サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1730960

壊死性腸炎の世界市場レポート 2025年

Necrotizing Enterocolitis Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
壊死性腸炎の世界市場レポート 2025年
出版日: 2025年05月16日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

壊死性腸炎市場規模は、今後数年間で力強い成長が見込まれます。2029年には複合年間成長率（CAGR）6.4％で66億2,000万米ドルに成長します。今後の見通しとしては、ヘルスケアコストの増加、潰瘍性大腸炎（UC）の罹患率と有病率の上昇、消化器疾患の増加、老年人口と肥満人口の増加、高齢者層の拡大といった要因が予測期間中の成長を牽引すると考えられます。予測期間中に予想される主な動向には、NEC早期発見のためのバイオマーカー研究の発展、非侵襲的検査法の進歩、高度モニタリングシステムの採用、手術技術の向上、標的療法の開発などがあります。

早産児数の増加が壊死性腸炎（NEC）市場の成長を牽引すると予想されます。未熟児出産（早産）は、一般的な妊娠期間が40週であるのに対し、妊娠37週未満で出産される場合に発生します。早産児の増加は、早産のリスクを高める高血圧、糖尿病、感染症などの母親の健康状態や、喫煙、薬物使用、栄養不良などのライフスタイル要因に起因しています。未熟児は消化器系が未発達であるため、炎症や感染症にかかりやすく、壊死性腸炎の影響を受けやすいです。例えば、2024年1月、米国疾病予防管理センターは、未熟児出産が米国における年間全出生の8.67％を占めると報告しました。その結果、早産児の増加がNEC市場の成長に寄与しています。

壊死性腸炎市場の各社は、未熟児における効果的な治療法という重大なアンメット・ニーズに対応するため、革新的な治療法の開発に注力しています。このような解決策の一つが無細胞の無菌生物学的製剤であり、培養細胞由来のタンパク質、成長因子、サイトカインなどの生理活性分子を含む精製された無菌の液体であるが、無傷の細胞は含まれていないです。これらの生物学的製剤は、治癒を促進し、炎症を抑えるように設計されています。例えば、2023年12月、米国を拠点とするバイオ医薬品会社Noveome Biotherapeutics, Inc.は、未熟児のNECを標的とする新規生物学的製剤ST266の第1-2相臨床試験を進める承認を米国食品医薬品局から取得しました。これは、ST266が30年以上ぶりにNECの主要な治療薬として開発される見込みであり、脆弱な人々の間でNECに関連する高い罹患率と死亡率を考慮すると、極めて重要なニーズに対応するものであるため、重要な進展となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の壊死性腸炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の壊死性腸炎市場：成長率分析
  • 世界の壊死性腸炎市場の実績：規模と成長、2019年～2024年
  • 世界の壊死性腸炎市場の予測：規模と成長、2024年～2029年、2034年
  • 世界の壊死性腸炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の壊死性腸炎市場：治療別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 完全静脈栄養（TPN）
  • 胃腸減圧
  • 抗菌療法
  • 抗真菌治療
  • 穿刺
  • その他の治療法
  • 世界の壊死性腸炎市場：診断別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 臨床検査
  • 画像技術
  • 世界の壊死性腸炎市場：ステージ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • ステージI（壊死性腸炎の疑い）
  • ステージII（確定的壊死性腸炎）
  • ステージIII（進行した壊死性腸炎）
  • 世界の壊死性腸炎市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 直接入札
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他の流通チャネル
  • 世界の壊死性腸炎市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 病院
  • 新生児集中治療室（NICU）
  • 専門クリニック
  • 世界の壊死性腸炎市場、完全静脈栄養（TPN）の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 標準的なTPN製剤
  • カスタマイズまたは個別化されたTPNソリューション
  • TPN用脂質乳剤
  • TPNにおけるタンパク質とアミノ酸のサプリメント
  • 微量栄養素および電解質強化TPN
  • 世界の壊死性腸炎市場、胃腸減圧術の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 経鼻胃管（NGチューブ）の減圧
  • 経口胃管減圧術
  • 減圧のための外科的胃瘻造設術
  • 非外科的減圧法
  • 世界の壊死性腸炎市場、抗菌療法の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 広域スペクトル抗生物質
  • グラム陽性菌被覆抗生物質
  • グラム陰性菌に対する抗生物質
  • 抗生物質の併用療法
  • ハイリスク新生児に対する予防的抗生物質戦略
  • 世界の壊死性腸炎市場、抗真菌治療のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 全身抗真菌療法
  • 早産児に対する予防的抗真菌療法
  • 重症NECに対する抗真菌薬と抗生物質の併用療法
  • 世界の壊死性腸炎市場、穿刺の種類によるサブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 診断的穿刺
  • 治療的穿刺
  • 超音波または放射線技術を用いたガイド下穿刺
  • 世界の壊死性腸炎市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • NEC予防のためのプロバイオティクスとプレバイオティクス
  • 外科的介入
  • 幹細胞療法と再生医療のアプローチ
  • 免疫調節療法
  • 支持療法

第7章 地域別・国別分析

  • 世界の壊死性腸炎市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 世界の壊死性腸炎市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 壊死性腸炎市場：競合情勢
  • 壊死性腸炎市場：企業プロファイル
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Mayo Foundation for Medical Education and Research Overview, Products and Services, Strategy and Financial Analysis
    • Cleveland Clinic Overview, Products and Services, Strategy and Financial Analysis
    • Boston Children's Hospital Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Hollister Incorporated
  • UPMC Children's Hospital of Pittsburgh
  • Prolacta Bioscience Inc.
  • Evolve BioSystems
  • Sigma-Tau Pharmaceuticals
  • Mead Johnson & Company LLC
  • Liminal BioSciences Inc.
  • Noveome Biotherapeutics Inc.
  • Infant Bacterial Therapeutics
  • Prometic Life Sciences Inc.
  • Nexilico
  • Siolta Therapeutics
  • ProThera Biologics Inc.
  • Plakous Therapeutics Inc.
  • Chosen Diagnostics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 壊死性腸炎市場2029年：新たな機会を提供する国
  • 壊死性腸炎市場2029年：新たな機会を提供するセグメント
  • 壊死性腸炎市場2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34632

Necrotizing enterocolitis (NEC) is a severe, potentially life-threatening gastrointestinal disorder that primarily affects premature infants. It is characterized by inflammation and tissue death (necrosis) in the intestines, which can lead to complications such as perforation and infection. Common symptoms of NEC include feeding intolerance, abdominal bloating, vomiting, and changes in bowel movements.

The primary treatment options for necrotizing enterocolitis include total parenteral nutrition (TPN), gastrointestinal decompression, antimicrobial therapy, antifungal treatment, paracentesis, and other interventions. TPN provides essential nutrients directly into the bloodstream, allowing the intestines to rest and heal, which is particularly beneficial for infants with NEC. Diagnosis involves various laboratory tests and imaging techniques across multiple stages stage I (suspected NEC), stage II (definite NEC), and stage III (advanced NEC). These treatments are distributed through several channels, such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and more, and are used in settings such as hospitals, neonatal intensive care units (NICUs), and specialty clinics.

The necrotizing enterocolitis market research report is one of a series of new reports from The Business Research Company that provides necrotizing enterocolitis market statistics, including the necrotizing enterocolitis industry global market size, regional shares, competitors with the necrotizing enterocolitis market share, detailed necrotizing enterocolitis market segments, market trends, and opportunities, and any further data you may need to thrive in the necrotizing enterocolitis industry. This necrotizing enterocolitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The necrotizing enterocolitis market size has grown strongly in recent years. It will grow from $4.83 billion in 2024 to $5.16 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth observed during the historic period can be attributed to factors such as the rising incidence of necrotizing enterocolitis, growing populations, higher per capita income, increased government funding, and a rise in premature births.

The necrotizing enterocolitis market size is expected to see strong growth in the next few years. It will grow to $6.62 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. Looking ahead, the growth during the forecast period can be driven by factors such as increasing healthcare costs, the rising incidence and prevalence of ulcerative colitis (UC), the growing number of gastrointestinal diseases, the increase in geriatric and obese populations, and the expanding elderly demographic. Key trends expected in the forecast period include advancements in biomarker research for early NEC detection, progress in non-invasive testing methods, adoption of advanced monitoring systems, improvements in surgical techniques, and the development of targeted therapies.

The rising number of premature births is expected to drive the growth of the necrotizing enterocolitis (NEC) market. Premature births, or preterm births, occur when a baby is delivered before 37 weeks of gestation, compared to the typical 40-week term. The increase in premature births is attributed to maternal health conditions such as high blood pressure, diabetes, and infections, which elevate the risk of preterm labor, as well as lifestyle factors such as smoking, drug use, and poor nutrition. Premature infants are more vulnerable to necrotizing enterocolitis because their gastrointestinal systems are underdeveloped, making them more susceptible to inflammation and infection. For example, in January 2024, the Centers for Disease Control and Prevention reported that premature births account for 8.67% of all births in the U.S. annually. As a result, the rise in premature births is contributing to the growth of the NEC market.

Companies in the necrotizing enterocolitis market are focusing on developing innovative treatments to address the critical unmet needs for effective therapies in premature infants. One such solution is cell-free sterile biologic solutions, which are purified, sterile liquids containing bioactive molecules such as proteins, growth factors, and cytokines derived from cultured cells but without intact cells. These biologic solutions are designed to promote healing and reduce inflammation. For instance, in December 2023, Noveome Biotherapeutics, Inc., a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration to proceed with a Phase 1-2 clinical trial for ST266, a novel biologic targeting NEC in premature infants. This marks a significant advancement, as ST266 is expected to be the first major therapeutic development for NEC in over three decades, addressing a critical need given the high morbidity and mortality rates associated with the disease among vulnerable populations.

In January 2025, Siolta Therapeutics, a U.S.-based developer of novel live biotherapeutics for NEC, partnered with Cowellnex Co. to combat the disease in premature infants. This collaboration combines Siolta's expertise in microbial science with Cowellnex's strength in microbiome drug discovery. By leveraging Siolta's Precision Symbiotics Platform, the partnership aims to advance research and develop treatments for NEC in premature infants. Cowellnex Co. Ltd. is a biotechnology company focused on advancing microbiome drug discovery.

Major players in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children's Hospital, Hollister Incorporated, UPMC Children's Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in necrotizing enterocolitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the necrotizing enterocolitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The necrotizing enterocolitis market consists of revenues earned by entities providing services such as neonatal intensive care, nutritional support, medical monitoring and support, and parental counseling and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The necrotizing enterocolitis market also includes sales of feeding tubes, surgical instruments for resection, and anti-inflammatory drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Necrotizing Enterocolitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on necrotizing enterocolitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for necrotizing enterocolitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The necrotizing enterocolitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Total Parenteral Nutrition (TPN); Gastrointestinal Decompression; Antimicrobial Therapy; Antifungal Treatment; Paracentesis; Other Treatments
  • 2) By Diagnosis: Laboratory Tests; Imaging Techniques
  • 3) By Stage: Stage I (Suspected Necrotizing Enterocolitis); Stage II (Definite Necrotizing Enterocolitis); Stage III (Advanced Necrotizing Enterocolitis)
  • 4) By Distribution Channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
  • 5) By End-User: Hospitals; Neonatal Intensive Care Units (NICUs); Specialty Clinics
  • Subsegments:
  • 1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations; Customized Or Individualized TPN Solutions; Lipid Emulsions for TPN; Protein And Amino Acid Supplements In TPN; Micronutrient And Electrolyte-Enhanced TPN
  • 2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression; Orogastric Tube Decompression; Surgical Gastrostomy for Decompression; Non-Surgical Decompression Techniques
  • 3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics; Gram-Positive Coverage Antibiotics; Gram-Negative Coverage Antibiotics; Combination Antibiotic Therapy; Prophylactic Antibiotic Strategies For High-Risk Neonates
  • 4) By Antifungal Treatment: Systemic Antifungal Therapy; Prophylactic Antifungal Therapy For Preterm Infants; Combination Antifungal And Antibiotic Therapy For Severe NEC
  • 5) By Paracentesis: Diagnostic Paracentesis; Therapeutic Paracentesis; Guided Paracentesis using Ultrasound Or Radiological Techniques
  • 6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention; Surgical Interventions; Stem Cell Therapy And Regenerative Medicine Approaches; Immunomodulatory Therapies; Supportive Care
  • Companies Mentioned: Abbott Laboratories; Astellas Pharma Inc.; Mayo Foundation for Medical Education and Research; Cleveland Clinic; Boston Children's Hospital
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Necrotizing Enterocolitis Market Characteristics

3. Necrotizing Enterocolitis Market Trends And Strategies

4. Necrotizing Enterocolitis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Necrotizing Enterocolitis Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Necrotizing Enterocolitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Necrotizing Enterocolitis Market Growth Rate Analysis
  • 5.4. Global Necrotizing Enterocolitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Necrotizing Enterocolitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Necrotizing Enterocolitis Total Addressable Market (TAM)

6. Necrotizing Enterocolitis Market Segmentation

  • 6.1. Global Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Total Parenteral Nutrition (TPN)
  • Gastrointestinal Decompression
  • Antimicrobial Therapy
  • Antifungal Treatment
  • Paracentesis
  • Other Treatments
  • 6.2. Global Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Laboratory Tests
  • Imaging Techniques
  • 6.3. Global Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Stage I (Suspected Necrotizing Enterocolitis)
  • Stage II (Definite Necrotizing Enterocolitis)
  • Stage III (Advanced Necrotizing Enterocolitis)
  • 6.4. Global Necrotizing Enterocolitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Other Distribution Channels
  • 6.5. Global Necrotizing Enterocolitis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Neonatal Intensive Care Units (NICUs)
  • Specialty Clinics
  • 6.6. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Total Parenteral Nutrition (TPN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Standard TPN Formulations
  • Customized Or Individualized TPN Solutions
  • Lipid Emulsions for TPN
  • Protein And Amino Acid Supplements In TPN
  • Micronutrient And Electrolyte-Enhanced TPN
  • 6.7. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Gastrointestinal Decompression, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Nasogastric Tube (NG Tube) Decompression
  • Orogastric Tube Decompression
  • Surgical Gastrostomy for Decompression
  • Non-Surgical Decompression Techniques
  • 6.8. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Antimicrobial Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Broad-Spectrum Antibiotics
  • Gram-Positive Coverage Antibiotics
  • Gram-Negative Coverage Antibiotics
  • Combination Antibiotic Therapy
  • Prophylactic Antibiotic Strategies For High-Risk Neonates
  • 6.9. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Antifungal Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Systemic Antifungal Therapy
  • Prophylactic Antifungal Therapy For Preterm Infants
  • Combination Antifungal And Antibiotic Therapy For Severe NEC
  • 6.10. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Paracentesis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Diagnostic Paracentesis
  • Therapeutic Paracentesis
  • Guided Paracentesis using Ultrasound Or Radiological Techniques
  • 6.11. Global Necrotizing Enterocolitis Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Probiotics And Prebiotics for NEC Prevention
  • Surgical Interventions
  • Stem Cell Therapy And Regenerative Medicine Approaches
  • Immunomodulatory Therapies
  • Supportive Care

7. Necrotizing Enterocolitis Market Regional And Country Analysis

  • 7.1. Global Necrotizing Enterocolitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Necrotizing Enterocolitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Necrotizing Enterocolitis Market

  • 8.1. Asia-Pacific Necrotizing Enterocolitis Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Necrotizing Enterocolitis Market

  • 9.1. China Necrotizing Enterocolitis Market Overview
  • 9.2. China Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Necrotizing Enterocolitis Market

  • 10.1. India Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Necrotizing Enterocolitis Market

  • 11.1. Japan Necrotizing Enterocolitis Market Overview
  • 11.2. Japan Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Necrotizing Enterocolitis Market

  • 12.1. Australia Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Necrotizing Enterocolitis Market

  • 13.1. Indonesia Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Necrotizing Enterocolitis Market

  • 14.1. South Korea Necrotizing Enterocolitis Market Overview
  • 14.2. South Korea Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Necrotizing Enterocolitis Market

  • 15.1. Western Europe Necrotizing Enterocolitis Market Overview
  • 15.2. Western Europe Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Necrotizing Enterocolitis Market

  • 16.1. UK Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Necrotizing Enterocolitis Market

  • 17.1. Germany Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Necrotizing Enterocolitis Market

  • 18.1. France Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Necrotizing Enterocolitis Market

  • 19.1. Italy Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Necrotizing Enterocolitis Market

  • 20.1. Spain Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Necrotizing Enterocolitis Market

  • 21.1. Eastern Europe Necrotizing Enterocolitis Market Overview
  • 21.2. Eastern Europe Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Necrotizing Enterocolitis Market

  • 22.1. Russia Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Necrotizing Enterocolitis Market

  • 23.1. North America Necrotizing Enterocolitis Market Overview
  • 23.2. North America Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Necrotizing Enterocolitis Market

  • 24.1. USA Necrotizing Enterocolitis Market Overview
  • 24.2. USA Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Necrotizing Enterocolitis Market

  • 25.1. Canada Necrotizing Enterocolitis Market Overview
  • 25.2. Canada Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Necrotizing Enterocolitis Market

  • 26.1. South America Necrotizing Enterocolitis Market Overview
  • 26.2. South America Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Necrotizing Enterocolitis Market

  • 27.1. Brazil Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Necrotizing Enterocolitis Market

  • 28.1. Middle East Necrotizing Enterocolitis Market Overview
  • 28.2. Middle East Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Necrotizing Enterocolitis Market

  • 29.1. Africa Necrotizing Enterocolitis Market Overview
  • 29.2. Africa Necrotizing Enterocolitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Necrotizing Enterocolitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Necrotizing Enterocolitis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Necrotizing Enterocolitis Market Competitive Landscape And Company Profiles

  • 30.1. Necrotizing Enterocolitis Market Competitive Landscape
  • 30.2. Necrotizing Enterocolitis Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Mayo Foundation for Medical Education and Research Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Cleveland Clinic Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Boston Children's Hospital Overview, Products and Services, Strategy and Financial Analysis

31. Necrotizing Enterocolitis Market Other Major And Innovative Companies

  • 31.1. Hollister Incorporated
  • 31.2. UPMC Children's Hospital of Pittsburgh
  • 31.3. Prolacta Bioscience Inc.
  • 31.4. Evolve BioSystems
  • 31.5. Sigma-Tau Pharmaceuticals
  • 31.6. Mead Johnson & Company LLC
  • 31.7. Liminal BioSciences Inc.
  • 31.8. Noveome Biotherapeutics Inc.
  • 31.9. Infant Bacterial Therapeutics
  • 31.10. Prometic Life Sciences Inc.
  • 31.11. Nexilico
  • 31.12. Siolta Therapeutics
  • 31.13. ProThera Biologics Inc.
  • 31.14. Plakous Therapeutics Inc.
  • 31.15. Chosen Diagnostics Inc.

32. Global Necrotizing Enterocolitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Necrotizing Enterocolitis Market

34. Recent Developments In The Necrotizing Enterocolitis Market

35. Necrotizing Enterocolitis Market High Potential Countries, Segments and Strategies

  • 35.1 Necrotizing Enterocolitis Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Necrotizing Enterocolitis Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Necrotizing Enterocolitis Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer